Comparative Pharmacology
Head-to-head clinical analysis: ESTRACE versus ETHINYL ESTRADIOL LEVONORGESTREL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESTRACE versus ETHINYL ESTRADIOL LEVONORGESTREL.
ESTRACE vs ETHINYL ESTRADIOL; LEVONORGESTREL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estradiol, a form of estrogen, binds to and activates nuclear estrogen receptors (ERα and ERβ), leading to modulation of gene transcription and subsequent physiological effects including development of secondary sexual characteristics, regulation of reproductive cycle, and effects on bone density, lipid metabolism, and cardiovascular system.
Combination of ethinyl estradiol and levonorgestrel suppresses gonadotropins (FSH and LH) from the anterior pituitary, inhibiting ovulation. Also increases cervical mucus viscosity and induces endometrial changes that reduce implantation likelihood.
1 to 2 mg orally once daily for continuous estrogen replacement; 0.1% cream applied vaginally 1 to 2 times daily for atrophic vaginitis.
1 tablet (0.03 mg ethinyl estradiol / 0.15 mg levonorgestrel) orally once daily for 21 consecutive days, followed by 7 days of placebo
None Documented
None Documented
Terminal half-life: 13-27 hours (mean 19 hours); clinical context: supports once-daily dosing for hormone replacement.
Ethinyl estradiol: ~13-27 hours (terminal); Levonorgestrel: ~16-33 hours (terminal). Clinically, steady-state is reached within 5-7 days; elimination half-life supports once-daily dosing with potential accumulation.
Renal: 50-80% as glucuronide and sulfate conjugates; fecal: 10-20%; biliary: minor (<5%).
Renal: Ethinyl estradiol ~40% as glucuronide and sulfate conjugates; levonorgestrel ~20% as metabolites. Fecal: Ethinyl estradiol ~60%; levonorgestrel ~80% via biliary excretion.
Category C
Category D/X
Estrogen
Estrogen